f how human colon-cancer cells evolve and how they become immune to inhibitor-drug therapy. Their research came at the request of the Pathology and Oncology Department at Johns Hopkins University. The department was trying to understand how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug

an colon-cancer cells evolve and how they become immune to inhibitor-drug therapy. Their research was conducted at the request of the Pathology and Oncology Department at Johns Hopkins University. The department was trying to understand how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug

an colon-cancer cells evolve and how they become immune to inhibitor-drug therapy. Their research was conducted at the request of the Pathology and Oncology Department at Johns Hopkins University. The department was trying to understand how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug